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Background: Metabolic syndrome (MetS) is closely linked to the development of cardiovascular (CV) disease. In TNT, 10,001 patients with stable 
CHD were randomized to atorvastatin 10 or 80 mg and followed for a median of 4.9 years. Among patients with MetS, the primary composite 
endpoint (cardiac death, MI, stroke, resuscitated cardiac arrest) was reduced by 29% in the 80 mg group versus the 10 mg group (p<0.0001). In 
this post hoc analysis of TNT, we compared the ability of 18 novel biomarkers to predict the risk of major CV events (MCVE) among patients with 
stable CHD and MetS, with the prognostic value of conventional lipid risk factors.
Methods: This nested case-control sub-study of MetS patients in TNT included 221 patients with a primary event plus 305 patients with MetS 
without events. We evaluated the predictive value of LDL-C, triglycerides (TG), HDL-C and 18 novel biomarkers on the primary events. Biomarker and 
lipid levels were measured at the time of randomization (following an 8-week atorvastatin 10 mg run-in period).
Results: Levels of HDL-C measured at randomization were highly predictive of subsequent MCVEs (HR=0.40; 95% CI, 0.23-0.68; P<0.001). 
The association between LDL-C (HR=1.51; 95% CI, 0.90-2.51; P=0.1) and TG levels (HR=1.22; 95% CI, 0.96-1.56; P=0.1) at randomization for 
subsequent MCVEs were positive, but not statistically significant. Most of the non-lipid biomarkers measured were also not predictive of future 
MCVEs. The exceptions were osteopontin and s-ICAM, with lower levels being associated with a significantly higher risk of a MCVE.
Conclusion: In statin-treated patients with stable CHD and MetS, of the traditional lipid biomarkers measured at the time of randomization, only 
HDL-C was associated with an increased risk of a subsequent MCVE. Of the 18 non-lipid biomarkers measured, only osteopontin and s-ICAM were 
predictive of future events.
